ArticleZeitschrift fur Rheumatologie2018
[Sarcopenia and frailty in older patients with rheumatism].
Article in Zeitschrift fur Rheumatologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- [Frequency and severity of sarcopenia in patients with inflammatory and noninflammatory musculoskeletal diseases : Results of a monocentric study in a tertiary care center].Zeitschrift fur Rheumatologie · 2023Article
- [Sports and exercise therapy in inflammatory rheumatic diseases].Zeitschrift fur Rheumatologie · 2021Article
- [Rheumatological care in the Rheumazentrum Ruhrgebiet Rheumatism Center-a model for conurbations].Zeitschrift fur Rheumatologie · 2019Review
- [Promotion of physical activity for older patients with rheumatism : Characteristics of inflammatory rheumatic diseases against the background of physical activity recommendations].Zeitschrift fur Rheumatologie · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is an age-related generalized loss of muscle mass and muscle strength resulting in low physical performance, which can be observed in up to 50% of >80-year-old individuals. The consequences are manifold and sarcopenia is closely linked to frailty. Important risk factors are genetics/epigenetics, immobilization, malnutrition and anorexia, hormone deficiencies, chronic inflammation and raised levels of inhibitory factors of tissue regeneration. Thus, functional assessment of muscle strength and physical performance are central components of diagnosing sarcopenia, beyond the mere quantification of muscle mass. Currently, many interventional strategies are being tested, including exercise regimens, nutrition programs, hormone replacement and pharmacological strategies involving anabolic principles. According to the current data, training programs and medications have a high potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.